SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week
15 oct. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
08 oct. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease
07 oct. 2024 05h00 HE
|
Hemex Health
In Brief: Findings from studies in Türkiye and Ghana presented at ASCAT 19th Annual Scientific Conference demonstrate that the Gazelle™ Hb Variant Test is an effective tool for accurate and...
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
20 juin 2024 08h00 HE
|
Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
Sickle Cell Disease Treatment Market Worth $4.69 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
08 nov. 2023 02h53 HE
|
The Insight Partners
Pune, India, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Sickle cell disease (SCD) is the most common inherited blood disorder that affects the red blood cells. Treatments for SCD can relieve pain and help...
First Patient Enrolled in SeaStar Medical’s Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
20 juin 2023 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, June 20, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar Medical Announces Activation of First Clinical Site in Pivotal Trial with Selective Cytopheretic Device in Critically Ill Adults with Acute Kidney Injury
19 avr. 2023 08h00 HE
|
SeaStar Medical Holding Corporation
DENVER, April 19, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of...
New Study: Lowering Dementia Risk Takes Less BrainHQ Training than Expected
11 avr. 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Researchers report a relatively small amount of brain training is required to reduce dementia risk in the Body, Brain, Life for Cognitive...
SeaStar Medical’s Selective Cytopheretic Device to be Featured at the 5th Chronic Kidney Disease Drug Development Summit
24 févr. 2023 08h05 HE
|
SeaStar Medical Holding Corporation
DENVER, Feb. 24, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce...
SeaStar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury
09 févr. 2023 08h19 HE
|
SeaStar Medical Holding Corporation
Patient enrollment in pivotal clinical study expected to begin in March DENVER, Feb. 09, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical (Nasdaq: ICU), a medical device company developing proprietary...